SynAct Pharma AB will raise 1,007,539.20 SEK through the utilisation of series TO 1 subscription options

The utilisation period of SynAct Pharma AB’s (“SynAct”) series TO 1 subscription options, which were issued in connection with the company’s issue of units in May/June 2016, terminated on March 23, 2017. In total, 157 428 series TO 1 subscription options were utilised, which means a utilisation rate of approximately 7.8 percent. SynAct raised warrants approximately SEK 1,007,539.20 through subscription options before issue costs.

In total, 157 428 subscription options were utilized, which means that 157 428 new shares are registered with the Swedish Companies Registration Office. SynAct thus raised approximately SEK 1 million before issue costs of approximately SEK 57 thousand. The number of shares in SynAct will, after registration of the subscription options utilisation at the Swedish Companies Registration Office, comes to 12 417 449 shares and the share capital will amount to SEK 1,552,181.13.  

For questions regarding series TO 1 subscription options, please contact:

Sedermera Fondkommission

Tel: + 46 40-615 14 10

E-mail: info@sedermera.se

For further information about SynAct Pharma AB, please contact:

Jeppe Øvlesen                                                          Henrik Stage

CEO, SynAct Pharma AB                                    CFO, SynAct Pharma AB

Telephone: +45 28 44 75 67                            Telephone: +45 40 26 09 00
E-mail: joo@synactpharma.com                     E-mail: tj@synactpharma.com

This is information that SynAct Pharma AB is obliged to disclose under the EU market abuse regulation. The information was submitted by the above contact person for publication on 31 March 2017.